333 related articles for article (PubMed ID: 27312342)
1. Durable Complete Response from Metastatic Melanoma after Transfer of Autologous T Cells Recognizing 10 Mutated Tumor Antigens.
Prickett TD; Crystal JS; Cohen CJ; Pasetto A; Parkhurst MR; Gartner JJ; Yao X; Wang R; Gros A; Li YF; El-Gamil M; Trebska-McGowan K; Rosenberg SA; Robbins PF
Cancer Immunol Res; 2016 Aug; 4(8):669-78. PubMed ID: 27312342
[TBL] [Abstract][Full Text] [Related]
2. Persistence of multiple tumor-specific T-cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapy.
Zhou J; Dudley ME; Rosenberg SA; Robbins PF
J Immunother; 2005; 28(1):53-62. PubMed ID: 15614045
[TBL] [Abstract][Full Text] [Related]
3. HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human melanoma model.
Schrörs B; Lübcke S; Lennerz V; Fatho M; Bicker A; Wölfel C; Derigs P; Hankeln T; Schadendorf D; Paschen A; Wölfel T
Oncotarget; 2017 Apr; 8(17):28312-28327. PubMed ID: 28423700
[TBL] [Abstract][Full Text] [Related]
4. Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 Expression.
Parkhurst M; Gros A; Pasetto A; Prickett T; Crystal JS; Robbins P; Rosenberg SA
Clin Cancer Res; 2017 May; 23(10):2491-2505. PubMed ID: 27827318
[No Abstract] [Full Text] [Related]
5. Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions.
Lu YC; Yao X; Crystal JS; Li YF; El-Gamil M; Gross C; Davis L; Dudley ME; Yang JC; Samuels Y; Rosenberg SA; Robbins PF
Clin Cancer Res; 2014 Jul; 20(13):3401-10. PubMed ID: 24987109
[TBL] [Abstract][Full Text] [Related]
6. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response.
Robbins PF; Kassim SH; Tran TL; Crystal JS; Morgan RA; Feldman SA; Yang JC; Dudley ME; Wunderlich JR; Sherry RM; Kammula US; Hughes MS; Restifo NP; Raffeld M; Lee CC; Li YF; El-Gamil M; Rosenberg SA
Clin Cancer Res; 2015 Mar; 21(5):1019-27. PubMed ID: 25538264
[TBL] [Abstract][Full Text] [Related]
7. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells.
Robbins PF; Lu YC; El-Gamil M; Li YF; Gross C; Gartner J; Lin JC; Teer JK; Cliften P; Tycksen E; Samuels Y; Rosenberg SA
Nat Med; 2013 Jun; 19(6):747-52. PubMed ID: 23644516
[TBL] [Abstract][Full Text] [Related]
8. Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes.
Cohen CJ; Gartner JJ; Horovitz-Fried M; Shamalov K; Trebska-McGowan K; Bliskovsky VV; Parkhurst MR; Ankri C; Prickett TD; Crystal JS; Li YF; El-Gamil M; Rosenberg SA; Robbins PF
J Clin Invest; 2015 Oct; 125(10):3981-91. PubMed ID: 26389673
[TBL] [Abstract][Full Text] [Related]
9. Tumor-infiltrating BRAFV600E-specific CD4+ T cells correlated with complete clinical response in melanoma.
Veatch JR; Lee SM; Fitzgibbon M; Chow IT; Jesernig B; Schmitt T; Kong YY; Kargl J; Houghton AM; Thompson JA; McIntosh M; Kwok WW; Riddell SR
J Clin Invest; 2018 Apr; 128(4):1563-1568. PubMed ID: 29360643
[TBL] [Abstract][Full Text] [Related]
10. Identification of a mutated receptor-like protein tyrosine phosphatase kappa as a novel, class II HLA-restricted melanoma antigen.
Novellino L; Renkvist N; Rini F; Mazzocchi A; Rivoltini L; Greco A; Deho P; Squarcina P; Robbins PF; Parmiani G; Castelli C
J Immunol; 2003 Jun; 170(12):6363-70. PubMed ID: 12794170
[TBL] [Abstract][Full Text] [Related]
11. T-cell Responses to
Deniger DC; Pasetto A; Robbins PF; Gartner JJ; Prickett TD; Paria BC; Malekzadeh P; Jia L; Yossef R; Langhan MM; Wunderlich JR; Danforth DN; Somerville RPT; Rosenberg SA
Clin Cancer Res; 2018 Nov; 24(22):5562-5573. PubMed ID: 29853601
[No Abstract] [Full Text] [Related]
12. T cells associated with tumor regression recognize frameshifted products of the CDKN2A tumor suppressor gene locus and a mutated HLA class I gene product.
Huang J; El-Gamil M; Dudley ME; Li YF; Rosenberg SA; Robbins PF
J Immunol; 2004 May; 172(10):6057-64. PubMed ID: 15128789
[TBL] [Abstract][Full Text] [Related]
13. Isolation of a new melanoma antigen, MART-2, containing a mutated epitope recognized by autologous tumor-infiltrating T lymphocytes.
Kawakami Y; Wang X; Shofuda T; Sumimoto H; Tupesis J; Fitzgerald E; Rosenberg S
J Immunol; 2001 Feb; 166(4):2871-7. PubMed ID: 11160356
[TBL] [Abstract][Full Text] [Related]
14. Exome Sequencing to Predict Neoantigens in Melanoma.
Pritchard AL; Burel JG; Neller MA; Hayward NK; Lopez JA; Fatho M; Lennerz V; Wölfel T; Schmidt CW
Cancer Immunol Res; 2015 Sep; 3(9):992-8. PubMed ID: 26048577
[TBL] [Abstract][Full Text] [Related]
15. A ras-mutated peptide targeted by CTL infiltrating a human melanoma lesion.
Linard B; Bézieau S; Benlalam H; Labarrière N; Guilloux Y; Diez E; Jotereau F
J Immunol; 2002 May; 168(9):4802-8. PubMed ID: 11971032
[TBL] [Abstract][Full Text] [Related]
16. Persistence of CTL clones targeting melanocyte differentiation antigens was insufficient to mediate significant melanoma regression in humans.
Chandran SS; Paria BC; Srivastava AK; Rothermel LD; Stephens DJ; Dudley ME; Somerville R; Wunderlich JR; Sherry RM; Yang JC; Rosenberg SA; Kammula US
Clin Cancer Res; 2015 Feb; 21(3):534-43. PubMed ID: 25424856
[TBL] [Abstract][Full Text] [Related]
17. Antigen-specific TIL therapy for melanoma: A flexible platform for personalized cancer immunotherapy.
Kelderman S; Heemskerk B; Fanchi L; Philips D; Toebes M; Kvistborg P; van Buuren MM; van Rooij N; Michels S; Germeroth L; Haanen JB; Schumacher NM
Eur J Immunol; 2016 Jun; 46(6):1351-60. PubMed ID: 27005018
[TBL] [Abstract][Full Text] [Related]
18. Multiple HLA class II-restricted melanocyte differentiation antigens are recognized by tumor-infiltrating lymphocytes from a patient with melanoma.
Robbins PF; El-Gamil M; Li YF; Zeng G; Dudley M; Rosenberg SA
J Immunol; 2002 Nov; 169(10):6036-47. PubMed ID: 12421991
[TBL] [Abstract][Full Text] [Related]
19. Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy.
Robbins PF; el-Gamil M; Kawakami Y; Stevens E; Yannelli JR; Rosenberg SA
Cancer Res; 1994 Jun; 54(12):3124-6. PubMed ID: 8205528
[TBL] [Abstract][Full Text] [Related]
20. Neoantigen-Specific Adoptive Cell Therapies for Cancer: Making T-Cell Products More Personal.
Bianchi V; Harari A; Coukos G
Front Immunol; 2020; 11():1215. PubMed ID: 32695101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
